SCHEMBL1241600

SCHEMBL1241600

CCCOc1ccc(-c2ccc(OC(F)(F)F)cc2)cc1N(Cc1ccc(C(C)(C)C)cc1)C(=O)C(=O)O

nearest known ligand 0.51

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
SERPINE1 P05121 10/20 0.51
GCGR P47871 2/20 0.41
GIPR P48546 2/20 0.41
GLP1R P43220 1/20 0.41
NR1H4 Q96RI1 2/20 0.41
EPHX2 P34913 1/20 0.41
PPARD Q03181 3/20 0.39
PPARA Q07869 1/20 0.38
LTB4R2 Q9NPC1 1/20 0.38
PTGES O14684 1/20 0.37
ALOX5 P09917 1/20 0.37
PSEN1 P49768 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1241732 0.96 SERPINE1 (0.51) SERPINE1GCGRGIPRGLP1RNR1H4
SCHEMBL1241578 0.95 SERPINE1 (0.49) SERPINE1GCGRGIPRGLP1RNR1H4
SCHEMBL1242896 0.91 NR1H4 (0.42) SERPINE1GCGRGIPRGLP1RNR1H4
SCHEMBL1241501 0.89 SERPINE1 (0.54) SERPINE1GCGRGIPRGLP1RNR1H4
SCHEMBL1239090 0.89 SERPINE1 (0.57) SERPINE1GCGRGIPRGLP1RNR1H4
SCHEMBL1241446 0.88 NR1H4 (0.42) SERPINE1GCGRGIPRGLP1RNR1H4
SCHEMBL1242737 0.87 SERPINE1 (0.50) SERPINE1GCGRGIPRGLP1RNR1H4
SCHEMBL1241544 0.86 NR1H4 (0.41) SERPINE1GCGRGIPRGLP1RNR1H4
SCHEMBL1239734 0.86 SERPINE1 (0.54) SERPINE1GCGRGIPRGLP1RNR1H4
SCHEMBL1239796 0.86 SERPINE1 (0.48) SERPINE1GCGRGIPRGLP1RNR1H4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7884234-B2 N-[4-(tert-butyl)benzyl]-N-[4 -(trifluoromethoxy)biphenyl-3-yl]oxamic Acid; Inhibitors of plasminogen activator inhibitor-1 (PAI-1); thrombogenesis, fibrogenesis, accumulation of visceral fat, cell proliferation, angiogenesis INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2011-02-08 US disclosed
US-20090215899-A9 N-Phenyloxamide derivatives INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2009-08-27 US disclosed
EP-2072498-A1 N-PHENYLOXAMIDIC ACID DERIVATIVE Institute of Medicinal Molecular Design, Inc. (JP) 2009-06-24 EP disclosed
US-20080249175-A1 N-Phenyloxamide derivatives INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2008-10-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080249175-A1 N-Phenyloxamide derivatives SERPINE1, SERPINH1, F12 SERPINE1 1/4885GCGR 1724/4885GIPR 2082/4885
US-20090215899-A9 N-Phenyloxamide derivatives SERPINE1, SERPINH1, F12 SERPINE1 1/4885GCGR 1724/4885GIPR 2082/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.